FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/23/2023
Back to search
Official data from USPTO
H.F.M BY TICEBA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
05/23/2023
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
04/10/2021
Registration date
01/24/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/24/2023
Last transaction
01/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
01
Owner location
DE
Examiner
BLANE, SUZANNE
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "H.F.M.", underlined and above the wording "BY TICEBA", all in the color blue. The wording is surrounded by 8 rods having a small ball at each end and alternating in color, with every other one in the color blue and the others in the color green. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
Holders and representatives
Holders
D. G. (pessoa física)
Representatives
Sean K. Owens WOOD HERRON & EVANS LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Stem cells for scientific or research use; cell growth media for growing cells for scientific use
Class 5
Pharmaceutical drugspharmaceutical drugs for treatment of skin diseasesantibioticsimmune suppressantsanti-inflammatory pharmaceuticals; Pharmaceutical drugs for treatment of disease and disorders of the respiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe nervous systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive systemfor the treatment of blood diseases and disorders; Pharmaceutical and veterinary preparations for treatment of vertigomigrainenauseavomitingfor treatment of skin diseaseswound healing; Pharmaceutical preparations for anti-aging; Diagnostic agents for medical use; Preparations for medical purposesfor the treatment of skin diseases; Substances for medical usefor regeneration of tissue and anti-inflammation; Stem cells for medical purposes; Stem cells for veterinary purposes; Stem cells for aesthetic purposesfor anti-agingfor use in dermatology procedures; Somatic stem cell therapeuticsfor medical therapeutic use; Fibroblasts for medical use; Fibroblasts for aesthetic purposesfor use in dermatology procedures; Pharmaceutical implantsimplantable surgery bonesbone graftscellsbone marrow; Surgical implants derived from stem cellssurgical implants derived from living tissues and living stem cells; Surgical implants derived from fibroblastssurgical implants comprised of living fibroblasts tissue cells; Biological tissue for implantationimplants comprising living tissues; Cell growth media for growing cells for medical use; Pharmaceutical preparations for tissue regeneration; Vascular grafts; Living tissuesurgical implants comprised of living tissues; Biotechnologically engineered tissue productscell sheets/plasters for wound healing/burnseye lense graftsbone graftsbiological tissue graftshuman allograft tissue
Class 42
Stem cell research; scientific research and development and medical research and development in the field of stem cells; Scientific researchtesting and analysis services in the field of regenerative medicine and tissue engineering; Scientific research for medical purposes; Medical research; Research and development of new products for others; Consultancy in the field of pharmaceutical research; Providing information on medical and scientific research on pharmaceutical products; Biomedical research; Preparation of reports relating to scientific researchtechnical writing for others; Research in the field of biotechnology; Research in the field of gene therapy; Research and development in the field of immunology; Research and development in the field of antibodies; Research and development in the field of antibody technology; Research and development in the field of bacteriology; Research and development in the field of gene expression systems; Research and development in the field of vaccines; Research and development services for the pharmaceutical industry; Research and development services in the field of biotechnology; Development of industrial processesengineering of industrial processes to manufacture stem cells; Development of industrial processesin the field of regenerative medicine and tissue engineering;Industrial process research in the field of regenerative medicinetissue engineeringchemical engineering
Class 44
Medical services relating to the removaltreatmentprocessing and preservation of medical cells and human tissuestem cells and bone marrowalso in the field of regenerative medicineincluding tissue engineering; medical services in connection with the removaltreatment and processing of human tissue and stem cellshuman tissue and stem cell bank servicesincluding in the field of regenerative medicineincluding tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells
Publications
History of USPTO decisions and trademark events.
37 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/01/2023
FIMP
FINAL DISPOSITION PROCESSED
05/01/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/24/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/24/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/24/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/30/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/30/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2022
PUBO
PUBLISHED FOR OPPOSITION
11/08/2022
GPNX
NOTIFICATION PROCESSED BY IB
11/07/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/19/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/19/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/19/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/29/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/29/2022
GNRT
NON-FINAL ACTION E-MAILED
09/29/2022
CNRT
NON-FINAL ACTION WRITTEN
09/29/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2022
ALIE
ASSIGNED TO LIE
08/09/2022
NREV
NOTICE OF REVIVAL - E-MAILED
07/13/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/13/2022
PETG
PETITION TO REVIVE-GRANTED
07/13/2022
PROA
TEAS PETITION TO REVIVE RECEIVED
07/13/2022
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
07/13/2022
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
07/13/2022
RFNT
REFUSAL PROCESSED BY IB
01/15/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/28/2021
RFRR
REFUSAL PROCESSED BY MPU
12/28/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/02/2021
CNRT
NON-FINAL ACTION WRITTEN
12/01/2021
DOCK
ASSIGNED TO EXAMINER
11/30/2021
MAFR
APPLICATION FILING RECEIPT MAILED
07/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/28/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/25/2021
Continuous trademark protection
Get notified about every new filing that threatens H.F.M BY TICEBA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.